Lower ARV prices negotiated in Mexico
This article was originally published in Scrip
Executive Summary
Several pharmaceutical companies have reduced the prices of their antiretrovirals in Mexico following negotiations with the government there, the Mexican health ministry has said. Thanks to the reductions, the ministry estimates that it will save Ps310 million ($30.6 million) annually.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.